

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docket Number (Optional) 0002263USU/3061		Application Number 10/533,768	
				Applicant Chiarelli et al.		Filing Date May 4, 2005	
U. S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,341,785	07/27/1982	Marchi et al.	424	256		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
Adachi, Javier A. et al., "Rifaxamin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders," <i>Clinical Infectious Diseases</i> , February 15, 2006; Vol. 42, pp 541-547.							
Cottreau, Jessica et al., "Rifaxamin: a nonsystemic rifamycin antibiotic for gastrointestinal infections" Abstract from <i>Expert Review of Anti-Infective Therapy</i> , Vol. 8, Number 7, July 2010, pp. 747-760. Abstract only							
Hoover, William W., et al. "Antimicrobial Activity and Spectrum of Rifaximin, a New Topical Rifamycin Derivative," <i>Diagnostic Microbiology of Infectious Diseases</i> , 1993, Vol. 16: pp. 111-118.							
Merriam-Webster online dictionary: definitions of "local," "topical" and "transdermal" downloaded January 5, 2011 from http://www.merriam-webster.com/dictionary .							
Palazzini, E. et al., "Treatment of pyogenic skin infections with Rifaximin cream," <i>European Review for Medical and Pharmacological Sciences</i> , 1993, Vol. XV, pp. 87-92.							
EXAMINER	/Nissa Westerberg/			DATE CONSIDERED 03/09/2011			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609, Draw line through citation if not in conformance
and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449		Docket Number (Optional) 0002263USU/3061	Application Number 10/533,768
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Chiarelli et al.	
		Filing Date May 4, 2005	Group Art Unit 1618

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Parini, Paolo et al., "Effects of rifaxamin and paromomycin in the treatment of portal-systemic encephalopathy," Abstract, <i>Current Therapeutic Research</i> , Volume 52, Issue 1, July 1992; pp. 34-39 (downloaded from www.sciencedirect.com).
	Prasad, Errol S. et al., "In vitro Activity of Rifaxamin, a Topical Rifamycin Derivative Against <i>Chlamydia trachomatis</i> ," <i>Diagnostic Microbiology of Infectious Diseases</i> , 1993, Vol. 16, pp. 135-136.
	Scarpignato, Carmelo et al., "Rifaxamin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential," <i>Chemotherapy</i> , 2005, Vol. 51 (Suppl 1), pp. 36-66.
	Taylor, David N., "Rifaxamin, a Nonabsorbed Oral Antibiotic, Prevents Shigellosis after Experimental Challenge," <i>Clinical Infectious Diseases</i> , 2006; Vol. 42, pp. 1283-1288.
	Venturini, A.P. et al., "Transcutaneous Absorption of a Topical Rifamycin Preparation: Rifaximin (L/105), <i>Drugs Experimental Clinical Research</i> , 1987, Vol. XIII No. 4, pp.233-236.
	Weinstock, Leonard B., "Irritable Bowel Syndrome: Emergence of New Diagnostic and Treatment Options," Paper developed 10/13/2009 pp. 1-19, at Washington University School of Medicine, St.Louis, MO, unpublished, available at www.gidocctor.net

EXAMINER	DATE CONSIDERED
/Nissa Westerberg/	03/09/2011

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.